2026-05-21T23:03:29Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/186342024-02-27T15:07:12Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc García-Aranda, Marilina author Téllez, Teresa author McKenna, Lauraine author Redondo, Maximino author 2022-04-30 Nowadays, the identification of new therapeutic targets that allow for the development of treatments, which as monotherapy, or in combination with other existing treatments can contribute to improve response rates, prognosis and survival of oncologic patients, is a priority to optimize healthcare within sustainable health systems. Recent studies have demonstrated the role of Substance P (SP) and its preferred receptor, Neurokinin 1 Receptor (NK-1R), in human cancer and the potential antitumor activity of NK-1R antagonists as an anticancer treatment. In this review, we outline the relevant studies published to date regarding the SP/NK-1R complex as a key player in human cancer and also evaluate if the repurposing of already marketed NK-1R antagonists may be useful in the development of new treatment strategies to overcome cancer resistance. 10.3390/cancers14092255 2072-6694 Cancers http://hdl.handle.net/10668/20890 35565383 http://hdl.handle.net/20.500.12105/18634 NK-1R cancer drug repurposing personalized medicine resistance tachykinin tachykinin receptor targeted treatment Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance.